IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. IQVIA creates intelligent connections to deliver powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA Research & Development Solutions (RDS) is the full-service clinical development partner that leverages the power of IQVIA Connected Intelligence across your entire study, from study design to site selection, enrollment and execution, so you can deliver life-changing therapies faster and without compromise. Learn more at Research & Development - IQVIA




  • Today’s complex protocols and competing trials lead to exponentially greater challenges to recruiting and retaining qualified participants. IQVIA Patient Recruitment and Enablement delivers patient-focused and site-centric solutions to accelerate enrollment, enhance engagement, and deliver trials on time and on budget. 

  • In making the transition to decentralized clinical trials (DCTs), learn ways to gather insights into patient preferences and needs and apply them to the design and delivery phases of a study to drive efficiency and improved patient engagement.

  • Understand how losses from failed clinical trials can now be mitigated through the use of artificial intelligence (AI) and machine learning-driven platforms that identify sub-populations of patients within a clinical trial who could respond positively to a treatment.

  • In this white paper, read about the latest trends in digital biomarkers, their emerging applications and explore opportunities this creates for pharmaceutical companies.


  • Connect your clinical program with strong scientific and medical expertise, deep therapeutic insights, and unrivaled clinical trials experience to find the most direct route from breakthrough science to new therapies for patients.

  • Understand how losses from failed clinical trials can now be mitigated through the use of artificial intelligence (AI) and machine learning-driven platforms that identify sub-populations of patients within a clinical trial who could respond positively to a treatment.

  • Explore the key developments in the haematological cancer space and the unique challenges and critical factors for success regarding the development and commercialization of assets for this type of cancer.

  • Gain insight into the rapidly evolving biomarker landscape in oncology, from clinical development to regulatory uncertainties to commercial implications, in this white paper.

  • Shifting away from the reliance on chemotherapies and radiation treatments, explore how immuno-oncology (IO), targeted therapies associated with predictive biomarkers, is increasingly becoming standard treatment.

  • Biomarkers are indicators of a patient’s likelihood to respond to certain treatments. Learn how testing for predictive biomarkers can help oncologists make more informed treatment decisions.

  • This white paper explores the enablers of R&D breakthroughs in the treatment of neurological conditions, examines trends in how the pharmaceutical industry is embracing this momentous opportunity, and identifies critical success factors for central nervous system (CNS) innovators.



IQVIA Research & Development Solutions

4820 Emperor Blvd.

Durham, NC 27703



  • Discover how adaptive clinical trials are being used more frequently to accelerate therapeutic development and de-risk studies. 

  • Learn the ways in which the pharmaceutical industry needs to work faster, leaner, and smarter to keep up with the pace of innovation to drive patient outcomes forward.

  • As the cost of drug development continues to rise and clinical research becomes lengthier and more complex, biopharmaceutical companies must find efficient ways to deliver trials with greater speed and quality at scale.

  • A fundamental shift in approach is needed to increase efficiency and effectiveness of clinical monitoring, continuing to ensure overall study quality and patient safety while relying more on automation and predictive analytics to continuously evaluate progress, remotely.

  • Discover the challenges to maintaining pharmacovigilance (PV) standards and experienced the opportunities to reimagine PV strategies and accelerate the implementation of automation and process changes.

  • Life science regulatory respondents from a wide range of positions were surveyed to assess the impact of COVID-19 on regulatory processes. Read the results in the research paper to understand the impact of the pandemic and how the future has changed for regulatory compliance.

  • Biostatistics can prove to be a competitive advantage when drug development timelines are tight. IQVIA biostatisticians, through our expertise and advanced technology, help customers surface insights and therefore reduce risk, decrease costs, and improve the quality of submissions. 

  • IQVIA understands one FSP model does not fit all requirements. Our models have been designed to fit the breadth and depth of your needs. Together, we can help you transform business processes and increase efficiencies.

  • The experienced IQVIA Global Data Management team provides innovative, end-to-end solutions for the management and delivery of high-quality, integrated, timely data in Phase I-IV trials.

  • IQVIA FSP Advance combines expert functional resourcing with clinical services integration and innovative technology solutions to increase productivity and efficiency – advancing your FSP outsourcing solution to effectively deliver your research & development portfolio.

  • Optimize your clinical development with Functional Service Provider (FSP) models that deliver a flexible mix of functional expertise, resource management, and technology-enabled solutions for your global programs.

  • Read how instead of continuing to own the processes and systems that comprise a functional capability, one should consider the strategic bundling of resources, processes, and technology managed within a third-party organization.

  • Data management experts work with a four-step innovation process to create connected data flow and standards. Together, these steps address data challenges, while increasing efficiency and optimizing quality. Explore each step in this white paper.

  • Discover how R and Python has become a powerful set of tools for statisticians and are being used extensively within drug development—from molecule to market.

  • Adaptive designs can be applied across all phases of clinical research, however guidance from experienced biostatisticians is critical to pairing the adaptive design option with development phase and trial objectives.

  • Learn a few examples of how advancing traditional FSP models can leverage advanced technologies with the power to support CRAs, while making their jobs easier and delivering added value for site staff, patients and sponsors.